R76
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 6
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.280
- WNT_BETA_CATENIN_SIGNALING+0.240
- P53_PATHWAY+0.200
- MYOGENESIS+0.190
- TNFA_SIGNALING_VIA_NFKB+0.110
- APICAL_JUNCTION+0.100
- COAGULATION+0.080
- ESTROGEN_RESPONSE_EARLY+0.060
- ANGIOGENESIS+0.040
- APICAL_SURFACE+0.040
Top 10 suppressed
- G2M_CHECKPOINT-0.600
- E2F_TARGETS-0.570
- PROTEIN_SECRETION-0.520
- MYC_TARGETS_V1-0.490
- MITOTIC_SPINDLE-0.430
- ALLOGRAFT_REJECTION-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.390
- ANDROGEN_RESPONSE-0.380
- OXIDATIVE_PHOSPHORYLATION-0.360
- MTORC1_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A3Z5-01A-41R-A24H-07 | — | A | 0.910 |
| 2 | SRR12202483 | — | — | 0.909 |
| 3 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.898 |
| 4 | TCGA-A7-A426-01A-22R-A24H-07 | — | A | 0.866 |
| 5 | TCGA-E7-A4XJ-01A-11R-A26T-07 | — | — | 0.862 |
| 6 | TCGA-E2-A14U-01A-11R-A22K-07 | — | A | 0.859 |
| 7 | R71 | — | — | 0.857 |
| 8 | MNG656 | — | — | 0.857 |
| 9 | SRR5088900 | — | — | 0.844 |
| 10 | MDT-AP-1167 | Med | Medulloblastoma | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |